ClinicalTrials.Veeva

Menu

Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients (WITECMO-H)

U

University Hospital, Lille

Status

Completed

Conditions

Von Willebrand Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT03070912
2015_83
2017-A00256-47 (Other Identifier)

Details and patient eligibility

About

ECMO has improved the outcome of heart or respiratory failure and carcinogenic shock and are increasingly used. However bleeding complications occurring in up to 50% of patients are poorly understood and worsen the overall results. The aim is to investigate the occurence of bleeding and its frequency according to the type of ECMO either veno-arterial or veno-venous. The investigators also want to assess the relation of bleeding with von Willebrand Factor defects.

Enrollment

257 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • informed consent of patient or person in charge
  • patient supplied by an ECMO for cardiac or respiratory failure and referred to Lille University Hospital
  • patient affiliated to "french social security"

Exclusion criteria

  • pregnant woman
  • no consent
  • no affiliation to
  • patient affiliated to '
  • preexisting bleeding disorders

Trial contacts and locations

7

Loading...

Central trial contact

Sophie SUSEN, MD,PhD; Antoine RAUCH, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems